Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.

Volltext-Artikel, E-Books und Literaturhinweise aus dem EBSCO Discovery Service

"Artikel & mehr" berücksichtigt nur einen Teil der für die Bibliothek der Frankfurt UAS verfügbaren Datenbanken. Zur Übersicht in DBIS

Ergebnis verändern

einschränken: Volltextzugriff; Academic (peer-reviewed) journals
erweitern: Auch Volltexte der Artikel durchsuchen; Verwandte Themen suchen

Publikationstyp

Thema

erschienen in

Verlag

Geographic terms

Sprache

Datenbank

Erscheinungsjahr

Von:

Bis:

Treffer 1 - 25 von 1404, Suchdauer: 1.22s

12 3 4 5 6 7 8 9 10 11 weiter »

1
Implications of isolated MRD progression in newly diagnosed multiple myeloma treated with quadruplet therapy

von Luciano J. Costa ; Eva Medvedova ; Binod Dhakal ; et al.

Blood Cancer Journal, Vol 15, Iss 1, Pp 1-4 (2025)

Schlagworte: Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282
- View full text via DOI
Merkliste

2
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk

von Natalie S. Callander ; Rebecca Silbermann ; Jonathan L. Kaufman ; et al.

Blood Cancer Journal, Vol 14, Iss 1, Pp 1-8 (2024)

Schlagworte: Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282
- View full text via DOI
Merkliste

3
Humoral immune reconstitution following therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara‐KRd), autologous hematopoietic cell transplantation, and measurable residual disease‐response‐adapted treatment cessation

von Rebecca W. Silbermann ; Timothy Martin Schmidt ; Susan Bal ; et al.

eJHaem, Vol 4, Iss 3, Pp 775-778 (2023)

Schlagworte: immunodeficiency; measurable residual disease; multiple myeloma; Diseases of the blood and blood-forming organs; RC633-647.5
- View full text via DOI
Merkliste

4
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

von Rodriguez-Otero P. ; Ailawadhi S. ; Arnulf B. ; et al.

Schlagworte: Hematology/Oncology; Leukemia/Lymphoma; Treatments in Oncology
- View full text via BASE
Merkliste

5
P31 SINGLE-AGENT BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: FINAL ANALYSIS OF THE DREAMM-2 TRIAL

von Nooka, A. ; Cohen, A. ; Lee, H. ; et al.

HemaSphere ; volume 7, issue S2, page 27-28 ; ISSN 2572-9241
- View full text via BASE
Merkliste

6
B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA-3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL

von Rodríguez-Otero, P. ; Ailawadhi, S. ; Arnulf, B. ; et al.

HemaSphere ; volume 7, issue S2, page 7-8 ; ISSN 2572-9241
- View full text via BASE
Merkliste

7
The cost-effectiveness of guideline-recommended treatments for osteoarthritis: A systematic review.

von Mathieson, Stephanie ; Ferreira, Giovanni ; Jones, Caitlin M.P. ; et al.

Osteoarthritis & Cartilage. Nov2025, Vol. 33 Issue 11, p1274-1292. 19p.
- Zum Volltext (via ReDI)
Merkliste

8
ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma

von Dhakal, B ; Shah, N ; Kansagra, A ; et al.
- View full text via BASE
Merkliste

9
P940: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-4 STUDY

von Suvannasankha, A. ; Bahlis, N. ; Trudel, S. ; et al.

HemaSphere ; volume 6, page 830-831 ; ISSN 2572-9241
- View full text via BASE
Merkliste

10
System, process, and design implications of a reduced supply voltage microprocessor

von Allmon, R. ; Benschneider, B. ; Callander, M. ; et al.

1990 37th IEEE International Conference on Solid-State Circuits Solid-State Circuits Conference, 1990. Digest of Technical Papers. 37th ISSCC., 1990 IEEE International. :48-49 1990
- Volltextverfügbarkeit prüfen (via ReDI)
Merkliste

11
P965: FOLLOW-UP ANALYSIS OF THE RANDOMIZED PHASE II TRIAL OF BORTEZOMIB, LENALIDOMIDE, DEXAMTHASONE WITH/WITHOUT ELOTUZUMAB FOR NEWLY DIAGNOSED, HIGH RISK MULTIPLE MYELOMA (SWOG-1211)

von Usmani, S. ; Hoering, A. ; Ailawadhi, S. ; et al.

HemaSphere ; volume 6, page 855-856 ; ISSN 2572-9241
- View full text via BASE
Merkliste

12
HAPLN1 confers multiple myeloma cell resistance to several classes of therapeutic drugs.

von Mailee Huynh ; Hae Yeun Chang ; Dominique N Lisiero ; et al.

PLoS ONE, Vol 17, Iss 12, p e0274704 (2022)

Schlagworte: Medicine; Science
- View full text via DOI
Merkliste

13
P939: SYNERGISTIC EFFECTS OF LOW DOSE BELANTAMAB MAFODOTIN IN COMBINATION WITH A GAMMA-SECRETASE INHIBITOR (NIROGACESTAT) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-5 STUDY

von Nooka, A. ; Lonial, S. ; Grosicki, S. ; et al.

HemaSphere ; volume 6, page 829-830 ; ISSN 2572-9241
- View full text via BASE
Merkliste

14
Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design

von Nooka, AK ; Weisel, K ; Van De Donk, NWCJ ; et al.
- View full text via BASE
Merkliste

15
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

von Mateos M. -V. ; Blacklock H. ; Schjesvold F. ; et al.
- View full text via BASE
Merkliste

16
857TiP An open-label, multicenter, phase II study of CLR 131 in patients with relapsed or refractory (R/R) select B-cell malignancies (CLOVER-1) and expansion cohort in patients with waldenstrom macroglobulinemia (CLOVER-WaM)

von Ailawadhi, S. ; Chanan-Khan, A. ; Peterson, J. ; et al.

Annals of Oncology ; volume 32, page S784-S785 ; ISSN 0923-7534
- View full text via BASE
Merkliste

17
Impact of prolonged dose delays on response with belantamab mafodotin (belamaf; gsk2857916) treatment in dreamm-2 study: 13-month follow-up

von A. Medaglia ; A.D. Cohen ; H.C. Lee ; et al.

Hematology Reports, Vol 12, Iss s1 (2020)

Schlagworte: Diseases of the blood and blood-forming organs; RC633-647.5
- Zum Volltext in DOAJ
Merkliste

18
Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial

von Delforge M. ; Patel K. ; Eliason L. ; et al.

Schlagworte: Health-related quality of life; triple-class exposed; relapsed; refractory; multiple myeloma; idecabtagene vicleucel; standard regimens; KarMMa-3 clinical trial
- Volltextverfügbarkeit prüfen (via ReDI)
Merkliste

19
PF587 SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE (SPD) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

von Chen, C. ; Gasparetto, C. ; White, D. ; et al.

HemaSphere ; volume 3, issue S1, page 245 ; ISSN 2572-9241 2572-9241
- View full text via BASE
Merkliste

20
Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis

von Mahindra, A ; Hari, P ; Fraser, R ; et al.

Bone Marrow Transplantation: Official journal of the European Society for Blood and Marrow Transplantation. 52(12):1616-1622
- Volltextverfügbarkeit prüfen (via ReDI)
Merkliste

21
S1606 SAFETY AND EFFICACY OF COMBINATION OF SELINEXOR, DARATUMUMAB, AND DEXAMETHASONE (SDD) IN PATIENTS WITH MULTIPLE MYELOMA (MM) PREVIOUSLY EXPOSED TO PROTEASOME INHIBITORS AND IMMUNOMODULATORY DRUGS

von Gasparetto, C. ; Lentzsch, S. ; Schiller, G. ; et al.

HemaSphere ; volume 3, issue S1, page 740 ; ISSN 2572-9241 2572-9241
- View full text via BASE
Merkliste

22
PS1414 A PHASE 1B/2 STUDY OF SELINEXOR, CARFILZOMIB, AND DEXAMETHASONE (SKD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

von Gasparetto, C. ; Lentzsch, S. ; Schiller, G. ; et al.

HemaSphere ; volume 3, issue S1, page 650 ; ISSN 2572-9241 2572-9241
- View full text via BASE
Merkliste

23
Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation

von Uy, G L ; Costa, L J ; Hari, P N ; et al.

Bone Marrow Transplantation: Official journal of the European Society for Blood and Marrow Transplantation. 50(12):1513-1518
- Volltextverfügbarkeit prüfen (via ReDI)
Merkliste

24
Dieses Ergebnis aus Science Citation Index Expanded kann Gästen nicht angezeigt werden.
Login für vollen Zugriff.
- Zur Referenz in Web of Science
Merkliste

25
Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up

von Biran, N. ; Jacobus, S. ; Vesole, D. H. ; et al.

Publisher

Schlagworte: Oncology; Stem Cells; Transplants
- View full text via BASE
Merkliste

12 3 4 5 6 7 8 9 10 11 weiter »

Sie haben nicht gefunden, wonach Sie gesucht haben? Diese Services können Ihnen weiterhelfen.
Hilfe & Kontakt ǀ Fernleihe | Hilfe zur Fernleihe ǀ Literaturvorschlag| Literaturvorschlag